Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mace L Rothenberg

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2009
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumorsA Craig Lockhart, Mace L Rothenberg, Jakob Dupont, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunctionLarry J Schaaf, Lisa A Hammond, Stuart J Tipping, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumorsPatricia M LoRusso, Roy S Herbst, Danny Rischin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2008
Potential regional differences for the tolerability profiles of fluoropyrimidinesDaniel G Haller, Jim Cassidy, Stephen J Clarke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2008
Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancerH Charles Manning, Nipun B Merchant, A Coe Foutch, et al.
JNCI Cancer Spectrum|May 23, 2022
Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical TrialsNadine J McCleary, William S Harmsen, Ellana Haakenstad, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2009
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumorsA Craig Lockhart, Mace L Rothenberg, Jakob Dupont, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunctionLarry J Schaaf, Lisa A Hammond, Stuart J Tipping, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumorsPatricia M LoRusso, Roy S Herbst, Danny Rischin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2008
Potential regional differences for the tolerability profiles of fluoropyrimidinesDaniel G Haller, Jim Cassidy, Stephen J Clarke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2008
Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancerH Charles Manning, Nipun B Merchant, A Coe Foutch, et al.
JNCI Cancer Spectrum|May 23, 2022
Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical TrialsNadine J McCleary, William S Harmsen, Ellana Haakenstad, et al.
Pageof 6